08:00 , Feb 26, 2007 |  BC Week In Review  |  Clinical News

L-Annamycin: Phase I started

KAL began an open-label, dose-escalation, U.S. Phase I trial in 46 children and young adults with refractory or relapsed ALL and AML. Patients will receive a starting dose of 130 mg/m 2/day of L-Annamycin for...
07:00 , Jun 5, 2006 |  BioCentury  |  Product Development

ALL/CML pipeline

ALL/CML pipeline...
08:00 , Dec 12, 2005 |  BC Week In Review  |  Clinical News

L-Annamycin: Phase I/II started

KAL started an open-label, U.S. Phase I/II trial in up to 34 relapsed or refractory adult ALL patients. The Phase I portion of the trial will be dose-escalating in about 12 patients. Callisto Pharmaceuticals Inc....
07:00 , Jul 4, 2005 |  BC Week In Review  |  Clinical News

Annamycin regulatory update

FDA granted Orphan Drug designation to annamycin, a second-generation anthracycline, to treat acute lymphoblastic leukemia (ALL). Annamycin completed a Phase I/IIa trial in refractory leukemia. Callisto Pharmaceuticals Inc. (KAL), New York, N.Y.   Product: Annamycin...
07:00 , Apr 3, 2000 |  BC Week In Review  |  Clinical News

Annamycin: Started Phase II trial

Annamycin is in separate Phase I/II testing to treat refractory or relapsed leukemia. Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas   Product: Annamycin   Business: Cancer   Therapeutic category: Adjunct   Target: Topoisomerase   Description:...
07:00 , Apr 3, 2000 |  BioCentury  |  Finance

Janus denies any special insight

Incyte...
08:00 , Mar 28, 2000 |  BC Extra  |  Clinical News

Aronex starts Phase II with Annamycin

ARNX started a U.S. Phase II open label trial to assess safety and efficacy of Annamycin , a liposomal anthracycline, to treat refractory breast cancer in patients overexpressing P-glycoprotein in tumor cells. ARNX was up...
07:00 , May 3, 1999 |  BC Week In Review  |  Clinical News

Annamycin: Began Phase I/II testing

Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas   Product: Annamycin   Business: Cancer   Therapeutic category: Adjunct   Target: Topoisomerase   Description: Liposomal anthracycline analog that maintains drug concentration in tumor cells by evading P-glycoprotein...
07:00 , May 27, 1997 |  BC Week In Review  |  Clinical News

Annamycin anthracycline data

ARNX presented Phase I results in cancer patients who had failed other therapies. As reported at the Denver meeting of the American Society of Clinical Oncology, multiple courses of the agent were evaluated in 30...
08:00 , Mar 17, 1997 |  BC Week In Review  |  Clinical News

Annamycin anthracycline analog data

ARNX announced preliminary results of its Phase I dose-escalating safety trial of Annamycin in 30 patients with multi-drug resistant tumors. The patients primarily had breast, lung or colon cancer or melanoma. Patients who had failed...